Emerging oligonucleotide therapies for asthma and chronic obstructive pulmonary disease.
Chronic respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD) are disorders of the airways largely related to the presence of persistent inflammation. The approval of inhaled corticosteroids in the early 1970s pioneered a new age of therapy in treating chronic inflammatory airway diseases. This was the first time that an anti-inflammatory product was available to reduce the characteristic lung inflammation in airways and the associated obstruction, inflammation and hyper-responsiveness. Fast forward 40 years: corticosteroids are still an important therapeutic intervention; however, they exhibit limited use in moderate to severe asthma and COPD. Oligonucleotide therapies are an emerging class which include the antisense, the RNAi (siRNA and miRNA), the immunomodulatory, the aptamer and the decoy approaches. As these approaches are rather recent in the respiratory field, most are still early in development. Nevertheless, with limitations of current small molecule therapies and the hurdles faced with biologics, the use of oligonucleotides is relevant and the door is open to the development of this category of therapeutics. This review focuses on the major classes of oligonucleotides that are currently in late stage preclinical or clinical development for the treatment of asthma and COPD, and discusses the implications for their use as therapies for respiratory diseases.
Séguin
Rosanne M
RM
Topigen Pharmaceuticals, Inc., Immunology and Development Support, 2901 Rachel East Street, Suite 13, Montréal, Québec H1W 4A4, Canada. rosanne.seguin@topigen.com
Ferrari
Nicolay
N
D000818:Animals; D001249:Asthma / Q000276:immunology / Q000628:therapy*; D002986:Clinical Trials as Topic; D004353:Drug Evaluation, Preclinical; D006801:Humans; D007155:Immunologic Factors / Q000276:immunology / Q000627:therapeutic use; D009841:Oligonucleotides / Q000276:immunology / Q000627:therapeutic use*; D029424:Pulmonary Disease, Chronic Obstructive / Q000276:immunology / Q000628:therapy*; D034741:RNA, Small Interfering / Q000276:immunology / Q000627:therapeutic use
D007155:Immunologic Factors; D009841:Oligonucleotides; D034741:RNA, Small Interfering